Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 5/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28518933 | 0.90 | FFAR2 (0.41) | FFAR2RIPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL31479247 | 0.88 | RIPK1 (0.50) | FFAR2RIPK1 | |
| SCHEMBL21093668 | 0.88 | RIPK1 (0.50) | FFAR2RIPK1 | |
| SCHEMBL28520937 | 0.88 | FFAR2 (0.40) | FFAR2RIPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL2587508 | 0.84 | FFAR2 (0.38) | FFAR2RIPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL28526542 | 0.83 | FFAR2 (0.40) | FFAR2RIPK1CHRM2CHRM1CHRM3 | |
| SCHEMBL6183606 | 0.83 | FFAR2 (0.51) | FFAR2RIPK1ABCB1 | |
| SCHEMBL859599 | 0.83 | FFAR2 (0.51) | FFAR2RIPK1ABCB1 | |
| SCHEMBL5156869 | 0.83 | FFAR2 (0.51) | FFAR2RIPK1ABCB1 | |
| SCHEMBL475745 | 0.83 | FFAR2 (0.51) | FFAR2RIPK1ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10995084-B2 | Pyrrolidine derivative | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2021-05-04 | — | — | US | disclosed |
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2020-09-24 | — | — | US | disclosed |
| EP-3459941-A1 | PYRROLIDINE DERIVATIVE | Kissei Pharmaceutical Co., Ltd. (JP) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200299273-A1 | PYRROLIDINE DERIVATIVE | CALCRL, NPY1R, GRPR | FFAR2 634/4885RIPK1 1917/4885CHRM2 340/4885 |
| US-10995084-B2 | Pyrrolidine derivative | CALCRL, NPY1R, GRPR | FFAR2 634/4885RIPK1 1917/4885CHRM2 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.